Unknown

Dataset Information

0

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.


ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.

SUBMITTER: Kurup D 

PROVIDER: S-EPMC8023494 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9508099 | biostudies-literature
| S-EPMC7829205 | biostudies-literature
| S-EPMC8842186 | biostudies-literature
| S-EPMC7929057 | biostudies-literature
| S-EPMC9744481 | biostudies-literature
2023-05-28 | GSE228112 | GEO
2023-05-28 | GSE228111 | GEO
| S-EPMC9164439 | biostudies-literature
| S-EPMC9229041 | biostudies-literature
| S-EPMC8789660 | biostudies-literature